ATE535541T1 - ANGIOGENESIS INHIBITOR, PRODUCTION METHOD AND USE THEREOF - Google Patents

ANGIOGENESIS INHIBITOR, PRODUCTION METHOD AND USE THEREOF

Info

Publication number
ATE535541T1
ATE535541T1 AT04792769T AT04792769T ATE535541T1 AT E535541 T1 ATE535541 T1 AT E535541T1 AT 04792769 T AT04792769 T AT 04792769T AT 04792769 T AT04792769 T AT 04792769T AT E535541 T1 ATE535541 T1 AT E535541T1
Authority
AT
Austria
Prior art keywords
production method
angiogenesis inhibitor
protein
activity
polypeptide
Prior art date
Application number
AT04792769T
Other languages
German (de)
Inventor
Kei Yamana
Yasunori Nakayama
Yoshimasa Takahashi
Eiji Ochiai
Hitoshi Wada
Yoshiaki Azuma
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Application granted granted Critical
Publication of ATE535541T1 publication Critical patent/ATE535541T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)

Abstract

[PROBLEMS] –¡To provide a polypeptide having a novel structure and showing an activity of inhibiting angiogenesis or an activity of inhibiting osteoclastogenesis, and to provide a recombinant protein by constructing a method of purifying the above protein. To provide an ingredient useful in designing remedies for tendinitis, rheumatoid arthritis, arthritis deformans, malignant tumor, etc. [MEANS FOR SOLVING PROBLEMS] DA novel soluble polypeptide protein.
AT04792769T 2003-10-21 2004-10-21 ANGIOGENESIS INHIBITOR, PRODUCTION METHOD AND USE THEREOF ATE535541T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003360617 2003-10-21
JP2004143421 2004-05-13
PCT/JP2004/015620 WO2005037864A1 (en) 2003-10-21 2004-10-21 Novel protein and production process and use thereof

Publications (1)

Publication Number Publication Date
ATE535541T1 true ATE535541T1 (en) 2011-12-15

Family

ID=34467794

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04792769T ATE535541T1 (en) 2003-10-21 2004-10-21 ANGIOGENESIS INHIBITOR, PRODUCTION METHOD AND USE THEREOF

Country Status (8)

Country Link
US (1) US8617841B2 (en)
EP (1) EP1681302B1 (en)
JP (1) JP4761968B2 (en)
KR (1) KR101174684B1 (en)
AT (1) ATE535541T1 (en)
AU (1) AU2004282071B2 (en)
CA (1) CA2543406C (en)
WO (1) WO2005037864A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100145441A1 (en) * 2005-09-22 2010-06-10 Keiichi Fukuda Therapeutic agents for angiogenesis-related diseases comprising chondromodulin-i as active ingredient
EP3312191B1 (en) 2015-06-18 2020-11-25 Seoul National University R&DB Foundation Peptide for promoting bone formation or inhibiting bone resorption and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2350623A1 (en) * 1998-11-13 2000-05-25 Zymogenetics, Inc. Mammalian chondromodulin-like protein
DE60044138D1 (en) * 1999-09-29 2010-05-20 Teijin Ltd POLYPEPTIDES AND FOR THESE ENCODING GENES

Also Published As

Publication number Publication date
US20090313711A1 (en) 2009-12-17
AU2004282071B2 (en) 2010-11-18
AU2004282071A1 (en) 2005-04-28
CA2543406C (en) 2013-08-13
US8617841B2 (en) 2013-12-31
EP1681302A1 (en) 2006-07-19
JP4761968B2 (en) 2011-08-31
KR20060118447A (en) 2006-11-23
EP1681302B1 (en) 2011-11-30
CA2543406A1 (en) 2005-04-28
WO2005037864A1 (en) 2005-04-28
KR101174684B1 (en) 2012-08-16
JPWO2005037864A1 (en) 2007-11-22
EP1681302A4 (en) 2007-06-13

Similar Documents

Publication Publication Date Title
ATE420970T1 (en) IL-1 RECEPTOR BASED ANTAGONISTS AND METHODS OF PRODUCTION AND USE
CY2200155T2 (en) MOBILE PLANT UNITS AND SYSTEMS, METHODS FOR THE PRODUCTION OF DESALITATED WATER
ATE482235T1 (en) AGLYCOSYL-ANTI-CD154 (CD40 LIGAND) ANTIBODIES AND USES THEREOF
ATE465202T1 (en) HIGHLY FUNCTIONAL, HIGHLY BRANCHED OR HYPERBRANCHED POLYESTERS AND THEIR PRODUCTION AND USE
ATE311385T1 (en) THIAZOLE AND IMIDAZO(4,5-B)PYRIDINE COMPOUNDS AND THEIR USE AS PHARMACEUTICALS
ATE556713T1 (en) OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS P38 KINASE INHIBITORS
FR2868414B1 (en) PROCESS FOR THE PRODUCTION OF PARTICULATE ALPHA-ALUMINA AND PARTICULATE APHA-ALUMINA PRODUCED BY THIS PROCESS
ATE446949T1 (en) NEW A-LIPOMIC ACID DERIVATIVE AND USE THEREOF
ITRM20070351A1 (en) GENE CODIFYING AMBER PROTEIN 1 HAVING REGULATORY ACTIVITY OF THE SELF-FAILURE AND DEVELOPMENT OF THE CENTRAL NERVOUS SYSTEM
ATE454454T1 (en) MULTIFUNCTIONAL AND MULTIVALENT ANGIOGENESIS INHIBITORS
AU8330898A (en) Substituted heterocycles and their use in medicaments
BR0204867A (en) Metal and polyurethane laminates
DE50201565D1 (en) 2-THIO SUBSITUATED IMIDAZOLE DERIVATIVES AND THEIR USE IN PHARMACY
ATE535541T1 (en) ANGIOGENESIS INHIBITOR, PRODUCTION METHOD AND USE THEREOF
TR199900548A3 (en) Production of dosage units using low shear granulation.
BRPI0408117A (en) bifunctional heterocyclic compounds and methods of production and use thereof
DE50211985D1 (en) USE OF PYRIDINE-2,4-DICARBONS UREDIAMIDES AND PYRIMID IN-4,6-DICARBONS UREDIAMIDES FOR THE SELECTIVE INHIBITION OF COLLAGENASES
ATE475315T1 (en) AGENTS FOR THE BIOLOGICAL CONTROL OF FUNGAL PLANT DISEASES
ITMI20022704A1 (en) PROCEDURE FOR THE PRODUCTION OF MESITILENE AND DURENE.
MA26252A1 (en) FLOATING PLANT FOR THE TREATMENT OF HYDROCARBONS.
ATE269325T1 (en) N-HETEROCYCLYL-BENZENE OR PYRIDINE SULFONAMIDES FOR USE AS ANTI-THROMBOGEN AND ANTICOAGULANT COMPOUNDS
DE602004007200D1 (en) Ecstasy derivatives, immunogens and antibodies and their use for the detection of ecstasy-like drugs
ITBO990395A0 (en) CHAIN FOR THE MANUFACTURE OF TRACKS.
ATE346924T1 (en) P-GLYCOPROTEINS AND THEIR USES
ATE343679T1 (en) CENTERPIECE